Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Immucor, Inc.
Dealmaking Quarterly Statistics, Q4 2022
During Q4, biopharma merger and acquisition value reached $35.7bn and drew in $62.1bn in potential deal value from alliances. Device company M&A values reached $19.2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $4.8bn.
Bill Hawkins Appointed Chair At Tricuspid Valve Startup 4Tech
Medtech veteran Bill Hawkins is the new board chair of 4Tech, a startup developing transcatheter tricuspid valve repair devices.
Device/Diagnostics Quarterly Deal Statistics, Q1 2016
Device companies raised 50% more in Q1 2016 than the previous quarter, reaching $1.8 billion and led by debt offerings; diagnostic imaging acquisitions, such as Toshiba Medical Systems, were abundant. Diagnostics financings double in Q1, mostly from venture funding, including strong showing from liquid biopsy companies.
Deals Shaping the Medical Industry, April 2016
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in March 2016.
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
- Other Names / Subsidiaries
- BioArray Solutions Ltd.
- Organ-i, Inc.
- Sirona Genomics
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.